ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer.

$5.54  +0.24 (4.53%)
As of 07/01/2022 16:00:02 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Canada
Country of incorporation:  Canada
IPO date:  04/28/2017
Outstanding shares:  57,771,204
Average volume:  1,149,589
Market cap:   $316,586,198
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Valuation   (See tab for details)
PE ratio:   -1.28
PB ratio:   1.08
PS ratio:   9.03
Return on equity:   -100.36%
Net income %:   -808.72%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy